购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 靶点 筛选
  • Others
    (3)
TargetMol | Tags 通过 货期 筛选
  • 5日内发货
    (2)
  • 20日内发货
    (2)
  • 6-8周
    (2)
  • 8-10周
    (1)
筛选
搜索结果
TargetMol产品目录中 "

gp 2.5

"的结果
  • 抑制剂&激动剂
    4
    TargetMol | Inhibitors_Agonists
  • 重组蛋白
    3
    TargetMol | Recombinant_Protein
  • KGP-25
    T89157
    KGP-25,一种电压门控钠通道 1.8 (Nav1.8) 抑制剂,通过靶向周围神经系统 (PNS) 中的 Nav1.8 实现镇痛作用.此外,KGP-25 还能作用于中枢神经系统 (CNS) 中的 γ-氨基丁酸亚型 A 受体 (GABAA),用于全身麻醉.
    • 待询
    规格
    数量
  • CGP 25454A
    T10779104391-26-6
    CGP 25454A is a novel and selective antagonist of the presynaptic dopamine autoreceptor.
    • ¥ 1370
    5日内发货
    规格
    数量
  • P-gp inhibitor 5
    T636082451298-06-7
    P-gp inhibitor 5 是 P 糖蛋白 (P-gp) 的有效抑制剂,在 1.25 μM 和 2.5 μM 时 P-gp 抑制倍数分别为 2.5 和 3.0。P-gp inhibitor 5 对某些癌细胞表现出抗增殖效果。P-gp inhibitor 5 能够恢复细胞对 Vincristine 和 Paclitaxel 的敏感性,进而逆转 ABCB1 Flp-InTM-293 和 KBvin 的多药耐药 (MDR) 表型。
    • ¥ 10600
    6-8周
    规格
    数量
  • Indium (III) thiosemicarbazone 5b
    T849682345755-20-4
    Indium (III) thiosemicarbazone 5b is an anticancer compound demonstrating cytotoxicity against various cancer cell lines including A549, MCF-7 breast, cisplatin-resistant MCF-7/DDP breast, and Hl 7702 liver cancer cells, with IC50 values of 2.41, 1.97, 2.11, and 8.95 µM, respectively. It effectively lowers PI3K, Akt, mTOR, P-gp, and GSH levels in MCF-7/DDP cells. In vivo studies show that at a dosage of 2.5 µmol/kg, indium (III) thiosemicarbazone 5b significantly reduces tumor weight and volume in MCF-7/DDP mouse xenograft models. Furthermore, liposomes formulated with this compound promote apoptosis and pro-death autophagy in MCF-7/DDP cells, alongside notable reductions in tumor volume and weight, showcasing its potential as a therapeutic agent in cancer treatment.
    • 待询
    8-10周
    规格
    数量